NCT04256980View on ClinicalTrials.gov

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

January 29, 2021

Study Completion Date

August 31, 2023

Conditions
Cholangiocarcinoma
Interventions
DRUG

Pemigatinib

Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule

Trial Locations (1)

Unknown

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04256980 - Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | Biotech Hunter | Biotech Hunter